title: Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Martin
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Hoffman
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Freimuth
authors.affiliation: Department of Genetics, Stanford University, Stanford, California, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.affiliation: Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Dong
authors.affiliation: Department of Pharmacology, University of Liverpool, Liverpool, UK.
authors.forename: M
authors.initials: M
authors.lastname: Pirmohamed
authors.affiliation: Department of Pharmacy and Center for Personalized Healthcare, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: J K
authors.initials: JK
authors.lastname: Hicks
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Wilkinson
authors.affiliation: Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
authors.forename: D W
authors.initials: DW
authors.lastname: Haas
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Kroetz
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D015224:Dideoxynucleosides / Q000008:administration & dosage*; D057286:Electronic Health Records; D005838:Genotype; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D000099227:Abacavir